lower-extremity deep vein thrombosis.' The authors rightfully claim to have found a &dquo;bug&dquo; in one of our trees. This bug actually reflected a clinically reasonable hypothesis, that calf deep vein thrombosis could directly lead to pulmonary embolism rather than progressing first through local extension to thigh vein thrombosis, but was not our intention. The authors do not provide convincing evidence that the consequences of this &dquo;mistake&dquo; lead to meaningful changes in the conclusion of the model.
The authors suggest that the DRIPS approach is superior to traditional manually constructed decision trees. This could be true, but a single critique of a published analysis does not make for a revolutionary breakthrough. Just as clinical prediction rules are rarely as powerful (when prospectively applied to a new dataset) as they appear in the development set, the DRIPS approach needs to prove its power when applied to new questions. Time will tell whether the learning curve of this software is short; whether the claimed modularity, compared with subtrees and boolean nodes, to speed selection of strategies is functional; whether its effectiveness in limiting or eliminating bugs is real; whether it can be made available on a standard personal computer; and whether an intelligible user manual is available. I will putter with it in the future and I encourage other members to try it. However, I doubt that DRIPS is a revolutionary step forward. status. How confident can we be in this assumption on which the conclusions of the analysis depend? Recent reviews of treatment of IgA nephropathy 4 indicate that no treatment has been shown in prospective trials to have a long-term benefit with regard to the progression of renal insufficiency. The data supporting the efficacy of Ig are derived from a single uncontrolled trial of 11 patients with IgA nephropathy with a median follow-up period of only 14 months. For a non-controlled trial, the results were striking; all patients in whom renal function had been declining before treatment had decreases in the rates of decline after treatment, and the median decline in glomerular filtration rate (GRF) of nearly 4 mL/month before treatment was reduced to zero after treatment. If these results prove to be reproducible and persistent, Ig therapy would certainly result in less dialysis for patients with IgA nephropathy. Nevertheless, because of the small number of patients, the uncontrolled study design, and the limited duration of follow-up, these results must be considered preliminary. It is not certain that the benefit of treatment will persist for the ten-year time horizon of the cost analysis. If the actual efficacy proves to be less or if the duration of benefit is shorter, the conclusions of the analysis might be changed.
To the extent that dialysis is avoided by treatment, it is clear that overall clinical outcomes would be improved. It is well documented that end-stage renal disease (ESRD) and dialysis are associated with an inferior quality of life . Moreover, patients who have ESRD have an average life expectancy that is only seven additional years, compared with 30 additional years for patients of the same age from the general population.' The risks and morbidity of Ig therapy would have to be strikingly high to offset this difference.
One cannot justify adoption of a medical intervention merely because it reduces costs. 8 9 The argument in favor of an intervention based on cost savings is really an argument for dominance over competing strategies. This requires quantifying the effects of treatment, both positive and negative, on quality-adjusted life expectancy and establishing that the net effect is favorable. The analysis must permit sensitivity analysis to explore the conditions for which dominance will pertain. For example, the cost of dialysis estimated by Durand-Zaleski and colleagues ($100,000 per year) is much higher than estimates of $36,000 to $51,000 cited for patients in the United States.1o Would Ig therapy still dominate no treatment if the cost for dialysis were substantially lower? If not, then the decision about treatment would have to be made on the basis of a favorable marginal cost-effectiveness ratio.ll This cannot be done with qualitatively estimated health outcomes. Quantifying health effects enables an analysis to detect the boundaries of dominance. This ensures a more complete understanding of the circumstances in which a health intervention will both reduce costs and improve outcomes. 
